

## Reviewer Relationships With Industry and Other Entities (Comprehensive)—2019 ACC Health Policy Statement on Cardiologist Compensation and Opportunity Equity

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Akshay Khandelwal	Official Reviewer—ACC Board of Governors	Henry Ford Hospital—Senior Staff, Interventional Cardiology, and Associate Division Head, Cardiology; Wayne State University—Clinical Associate Professor	None	None	None	None	• Henry Ford Health System Finance Committee*	None
Dharam Kumbhani	Official Reviewer—Solution Set Oversight Committee (SSOC)	University of Texas (UT) Southwestern Medical Center—Assistant Professor, Interventional Cardiology, Department of Internal Medicine	• ACC†	None	None	None	None	None
Nicole M. Bhave	Content Reviewer—Solution Set Oversight Committee	University of Michigan—Assistant Professor of Cardiovascular Medicine.	None	None	None	None	None	None
Ann B. Curtis	Content Reviewer—ACC Expert	The State University of New York (SUNY)—Distinguished Professor, Charles and Mary Bauer Professor, Chair, Department of Medicine	<ul style="list-style-type: none"> <li>• Abbott</li> <li>• ACC†</li> <li>• Biotronik</li> <li>• Janssen Pharmaceuticals</li> <li>• Medtronic†</li> <li>• Novartis</li> <li>• Sanofi Aventis</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Abbott</li> <li>• Medtronic (DSMB) †</li> </ul>	None	None
Gregory J. Dehmer	Content Reviewer—Solution Set Oversight Committee	Carilion Clinic, Cardiology & Carilion Cardiovascular Institute—Medical Director, Quality and Outcomes; Virginia Tech Carilion School of Medicine	<ul style="list-style-type: none"> <li>• American Board of Internal Medicine</li> <li>• CMS MedCAC Panel</li> <li>• FDA Circulatory System Devices Panel of the Medical Devices</li> </ul>	None	None	• SCAI*	None	None

			Advisory Committee					
Claire Duvernoy	Content Reviewer—Women in Cardiology Council, Chair; Inclusiveness and Diversity Task Force	Ann Arbor Healthcare System—Cardiology Section; VA; University of Michigan Health System—Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> <li>• Kowa Research Institute‡</li> <li>• VA Cooperative Studies Program*</li> </ul>	None
Robert C. Hendel	Content Reviewer—ACC Expert	Tulane University School of Medicine—Sidney W. and Marilyn S. Lassen Chair in Cardiovascular Medicine; Chief, Section of Cardiology; Tulane University Heart & Vascular Institute—Director	None	None	None	None	None	<ul style="list-style-type: none"> <li>• Defendant, Overuse/fraud, 2018</li> </ul>
Darilyn V. Moyer	Content Reviewer—ACC Expert	American College of Physicians—Executive Vice President and CEO, Executive Office	None	None	None	None	None	None
Cheryl B. Pegus	Content Reviewer—Inclusiveness and Diversity Task Force	Regence, Cambia Health Solutions—SVP, Healthcare Services and Chief Medical Officer	None	None	<ul style="list-style-type: none"> <li>• Tactile Medical†</li> <li>• USACS†</li> </ul>	None	None	None
Andrea L. Price	Content Reviewer—Solution Set Oversight Committee; Cardiovascular Team Council	Indiana University Health—Director- Quality Databases	None	None	None	<ul style="list-style-type: none"> <li>• ACC Accreditation Foundation Board†</li> </ul>	None	None
Toniya Singh	Content Reviewer—ACC Expert and Women in Cardiology Council	St Louis Heart and Vascular—Managing Partner; National Women in Cardiology—Chair	None	None	None	<ul style="list-style-type: none"> <li>• AstraZeneca Pharmaceuticals</li> <li>• Bayer†</li> <li>• St. Louis Heart and Vascular†</li> </ul>	<ul style="list-style-type: none"> <li>• AstraZeneca Pharmaceuticals‡</li> <li>• Bristol-Myers Squibb‡</li> <li>• Janssen Pharmaceuticals‡</li> <li>• Medtronic‡</li> <li>• Novartis‡</li> <li>• Pfizer‡</li> </ul>	None

Edward Toggart	Content Reviewer— Seniors Council	Samaritan Heart and Vascular Institute— Director, Cardiac Cath Lab; Director, Interventional Cardiology; Director of Quality Improvement	None	None	None	None	None	None
George W, Vetrovec	Content Reviewer— Seniors Council	Virginia Commonwealth University (VCU)— Professor of Medicine; Chair, Division of Cardiology, VCU Pauley Heart Center	<ul style="list-style-type: none"> <li>• Abiomed†</li> <li>• FDA CV Device Panel Committee</li> <li>• Merck</li> </ul>	None	<ul style="list-style-type: none"> <li>• Johnson &amp; Johnson†</li> <li>• Merck†</li> <li>• Pfizer†</li> </ul>	<ul style="list-style-type: none"> <li>• Biocarcia (DSMB)</li> </ul>	None	None
David E. Winchester	Content Reviewer— Solution Set Oversight Committee	University of Florida College of Medicine (UFCOM)—Associate Professor of Medicine; Malcom Randall VAMC— Staff Cardiologist; Assistant Cardiology Fellowship Program Director, Quality and Research; Co-Director, Advanced Fellowship for Cardiovascular Imaging; Co-Director, University of Florida (UF) Health Cardiac Imaging Group	None	None	None	<ul style="list-style-type: none"> <li>• NHLBI ISCHEMIA Trial Site*</li> </ul>	<ul style="list-style-type: none"> <li>• Alachua County Medical Society Board of Directors*</li> </ul>	None
Malissa J. Wood	Content Reviewer— Women in Cardiology Council	Massachusetts General Hospital—Co-Director MGH Heart Center Corrigan Women’s Heart Health Program	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$5,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

\*No financial benefit.

†Significant relationship.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

ACC=American College of Cardiology; CMS=The Centers for Medicare & Medicaid Services; DSMB=Data Safety Monitoring Board; FDA=Food and Drug Administration; MedCAC=Medicare Evidence Development & Coverage Advisory Committee; NHLBI= National Heart, Lung, and Blood Institute; NIH=National Institutes of Health; SCAI=Society for Cardiac Angiography and Interventions; VA=Department of Veterans Affairs; VAMC=Veterans Administration Medical Center.